Judge Dismisses Homeopathy Industry Challenge to FDA Policy Shift

A federal judge has dismissed a lawsuit brought by homeopathy advocates and a product distributor challenging FDA’s decision to tighten oversight of homeopathic drugs, ruling the plaintiffs failed to demonstrate legal standing.

In a memorandum opinion issued by judge Christopher R. Cooper of the U.S. District Court for the District of Columbia, the court granted summary judgment in favor of the federal government, effectively ending the case brought by the Alliance for Natural Health and distributor Meditrend, Inc.

The lawsuit centered on FDA’s 2022 denial of a citizen petition that sought to restore a more permissive regulatory framework for homeopathic products. Plaintiffs argued the agency’s decision was “arbitrary and capricious” under the Administrative Procedure Act and contributed to economic harm across the industry.

But the court concluded that the plaintiffs failed to show a sufficient causal link between FDA’s petition denial and the alleged injuries, such as lost retail business and increased supplier costs.

“The government is correct: Plaintiffs have not established the traceability and redressability prongs of standing,” Cooper wrote, emphasizing that plaintiffs must demonstrate a direct connection between the challenged agency action and their claimed harm.

The ruling marks the latest chapter in a broader shift in federal oversight of homeopathic drugs. For decades, FDA exercised enforcement discretion under a 1988 compliance policy that allowed such products to be marketed without formal approval, provided certain conditions were met. That approach began to change in the mid-2010s following reports of safety concerns.

The agency formally withdrew its longstanding policy in 2019 and later adopted a more risk-based enforcement framework, prioritizing action against products that pose higher safety risks. In 2022, it also rejected a petition from an industry-backed group seeking to reinstate a more lenient regime.

While the court previously allowed part of the case to proceed, it ultimately found that the remaining claim — focused on the petition denial — could not survive summary judgment because the plaintiffs did not provide sufficient evidence tying their business losses to that specific action.

The plaintiffs had argued that retailers, including Whole Foods, pulled their products and that suppliers raised prices due to increased regulatory scrutiny. However, the court found these claims were largely linked to earlier FDA actions, particularly the 2019 repeal of the agency’s prior enforcement policy, rather than the 2022 petition denial at issue in the case.

The decision leaves intact FDA’s current regulatory posture toward homeopathic drugs, which treats them more like conventional pharmaceuticals subject to safety and efficacy standards.

The case is Alliance for Natural Health USA et al. v. United States, No. 24-cv-2989, in the U.S. District Court for the District of Columbia.